SINOPHARM GROUP 1/5/O.N. Cash Flow-to-Debt Ratio
SINOPHARM GROUP 1/5/O.N. cash flow-to-debt ratio. SINOPHARM GROUP 1/5/O.N. (X2S1) has a Cash Flow-to-Debt Ratio of 0.06x as of December 2025, meaning its operating cash flow of €14.14 Billion could theoretically repay 0% of its total liabilities (€256.20 Billion) in one year. Check SINOPHARM GROUP 1/5/O.N. cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of SINOPHARM GROUP 1/5/O.N. (2021–2025)
Cash flow-to-debt ratio of SINOPHARM GROUP 1/5/O.N. from 2021 to 2025. Historical debt coverage capacity for SINOPHARM GROUP 1/5/O.N. across 5 annual periods. Check SINOPHARM GROUP 1/5/O.N. investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
SINOPHARM GROUP 1/5/O.N. Cash Flow-to-Debt Ratio by Year (2021–2025)
SINOPHARM GROUP 1/5/O.N. cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for SINOPHARM GROUP 1/5/O.N.. For the full cash flow conversion analysis, see X2S1 operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.06x | €14.14 Billion | €256.20 Billion | ▲ +27.2% |
| 2024 | 0.04x | €11.55 Billion | €266.14 Billion | ▼ -33.5% |
| 2023 | 0.07x | €17.17 Billion | €263.08 Billion | ▼ -20.7% |
| 2022 | 0.08x | €20.96 Billion | €254.71 Billion | ▲ +108.5% |
| 2021 | 0.04x | €9.31 Billion | €235.76 Billion | — |